2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole [Yahoo! Finance]
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: Yahoo! Finance
10 stocks we like better than BioAge Labs › BioAge Labs (NASDAQ: BIOA) is a small drugmaker whose shares have caught fire this year. The company has made clinical progress in the hottest therapeutic area in the industry right now: Weight management. BioAge Labs' shares are up by 122% year to date. Even after recent developments, however, BioAge Labs' shares remain unattractive for investors focused on the long term. It'd be best to stay far away from the stock. Here are two reasons why. As a rule, clinical-stage biotech companies are high-risk investments. But they aren't all the same. The more positive clinical trial results they have for their candidates, the less speculative they tend to be. So, a pre-commercial biotech with one or several products in phase 3 studies that have already produced strong results across multiple clinical trials is less risky (all else being equal) than one with products that haven't even advanced to mid-stage studies yet. Unfortunately, BioAge
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- Leqembi included in China's commercial insurance innovative drug listPR Newswire
- Leqembi included in China's commercial insurance innovative drug listPR Newswire
- BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BIOA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BIOA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating. They now have a $12.00 price target on the stock.MarketBeat
BIOA
Earnings
- 11/6/25 - Beat
BIOA
Sec Filings
- 12/11/25 - Form 4
- 12/9/25 - Form 144
- 12/5/25 - Form 4
- BIOA's page on the SEC website